Juno Therapeutics

Executives of Juno Therapeutics under investigation

Monday, August 14, 2017

Shareholder and consumer rights law firm Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of Juno Therapeutics breached their fiduciary duties to Juno and its shareholders by exposing Juno to civil liability for failing to disclose patient deaths in the phase II/ROCKET trial of its leading product candidate, JCAR015, during the period June 24, 2016, to November 22, 2016. 

[Read More]

Juno partners Memorial Sloan Kettering and Eureka Therapeutics

Tuesday, August 9, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, has entered into an exclusive license agreement with Memorial Sloan-Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.

[Read More]

Juno, WuXi launch JW Biotechnology in China

Monday, April 11, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and WuXi AppTec, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, have started a new company in China. JW Biotechnology (Shanghai) Co., Ltd‘s mission is to build China’s  cell therapy company by leveraging Juno’s world-class chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies together with WuXi AppTec’s R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solidorgan cancers. 

[Read More]

Celgene, Juno collaborate on cancer and autoimmune diseases

Wednesday, July 1, 2015

Celgene, headquartered in Summit, N.J., and Seattle-based Juno Therapeutics have formed a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies.

[Read More]

Juno Therapeutics acquires X-BODY

Wednesday, June 3, 2015

Juno Therapeutics, a Seattle-based biopharmaceutical company focused on re-engaging the body’s immune system to treat cancer, has acquired X-BODY, a privately held biotechnology company with nine employees based in Waltham, Mass. The acquisition furthers Juno’s strategy of investing in technologies that augment the company’s capabilities to create best-in-class engineered T cells against a broad array of cancer targets. The acquisition brings in-house to Juno an innovative discovery platform that interrogates the human antibody repertoire, rapidly selecting fully human antibodies with desired characteristics, even against difficult targets.

[Read More]